Development of an adjuvant-active nonionic block copolymer for use in oil-free subunit vaccines formulations

Vaccine
C W ToddM J Newman

Abstract

Nonionic block copolymers, synthesized from repeating units of oxypropylene and oxyethylene, can be designed so that individual copolymers have unique physical properties with differential levels of adjuvant activity. We have designed high molecular weight block copolymers that spontaneously assemble into 500 nm-3 mum particles when formulated with protein antigens in aqueous solutions at physiological pH. The adjuvant activity of one of these copolymers, termed CRL1005, was compared to selected research adjuvants using ovalbumin (OVA) as the prototype vaccine antigen. Suboptimal doses of OVA were formulated with complete and incomplete. Freund's adjuvant (CFA/IFA), alum Quil-A saponins Ribi Adjuvant System (RAS) or the CRL1005 copolymer and these formulations were used to immunize C57BL/6 mice. The CRL1005 copolymer appeared to be more potent than either Quil-A or alum and comparable to the RAS formulation, based on the numbers of responding mice and the OVA-specific antibody titers. Alum. RAS and Quil-A all augmented the production of IgG1 and IgG2l, similarly whereas only the CFA/IFA boosted IgG2a levels significantly. The effect of adjuvants on relative antibody affinity was more variable with the CRL1005 and CFA/IFA induci...Continue Reading

References

Jan 1, 1992·Vaccine·A W Heath, J H Playfair
Mar 1, 1991·Molecular Immunology·J H EldridgeR M Gilley
Feb 10, 1988·Journal of Immunological Methods·R A MacdonaldC L Jones
Apr 15, 1986·Cellular Immunology·L M Flebbe, H Braley-Mullen
Nov 15, 1974·Nature·A G Allison, G Gregoriadis
Aug 1, 1995·AIDS Research and Human Retroviruses·L B LachmanJ L Cleland
Jan 1, 1994·Biotherapy·A Nohria, R H Rubin
Oct 1, 1993·Immunology and Cell Biology·A D NashA E Andrews
Jan 1, 1993·Cancer Immunology, Immunotherapy : CII·G D MacLeanB M Longenecker

❮ Previous
Next ❯

Citations

May 20, 2004·Vaccine·Ya-Wun YangW J W Morrow
Aug 23, 2001·Journal of Controlled Release : Official Journal of the Controlled Release Society·V P Torchilin
Jun 6, 2000·Advanced Drug Delivery Reviews·C W ToddM J Newman
Nov 23, 2012·Journal of the Royal Society, Interface·Akhilesh Kumar Shakya, Kutty Selva Nandakumar
Jun 19, 2001·Biological Chemistry·W ZaunerM Buschle
Nov 13, 1998·Journal of Pharmaceutical Sciences·M J NewmanM Balusubramanian
Mar 13, 2009·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·Ming-Hsi HuangChih-Hsiang Leng
Apr 22, 2008·The Journal of Gene Medicine·Jukka HartikkaAlain Rolland
Jan 16, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Elena V BatrakovaAlexander V Kabanov
Nov 27, 2009·Nature·Jeffrey A HubbellMelody A Swartz
Jun 2, 2020·Expert Opinion on Drug Delivery·Rosana Simón-VázquezÁfrica González-Fernández

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.